CoChat

Comparison of disease progression subgroups in idiopathic pulmonary fibrosis

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 6 of the 13 sources its claims cite were checked for support.

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with an unpredictable course. The aims of this study were to retrospectively re-evaluate a cohort of patients with IPF according to the 2011 international IPF guidelines and 1) to characterize the subgroups of patients when classified according to their observed survival times and 2) to evaluate whether Composite Physiologic Index (CPI), Gender-Age-Physiology (GAP) Index or clinical variables could predict mortality. METHODS: Retrospective data was collected and patients were classified into subgroups according to their observed lifespans. Differences in clinical variables, CPI and GAP stages as well as in comorbidities were investigated between the subgroups. Predictors of mortality were identified by COX proportional hazard analyses. RESULTS: A total of 132 patients were included in this study. The disease course was rapid (≤ 2 years) in 30.0%, moderate (2-5 years) in 28.0% and slow (≥ 5 years) in 29.0% of the patients. Pulmonary function tests (PFT) and CPI at baseline differentiated significantly between the rapid disease course group and those patients with longer survival times. However, the predictive accuracy of the investigated clinical variables was mainly less than 0.80. The proportions of patients with comorbidities did not differ between the subgroups, but more patients with a rapid disease course were diagnosed with heart failure after the diagnosis of IPF. Most patients with a rapid disease course were categorized in GAP stages I and II, but all patients in GAP stage III had a rapid disease course. The best predictive multivariable model included age, gender and CPI. GAP staging had slightly better accuracy (0.67) than CPI (0.64) in predicting 2-year mortality. CONCLUSIONS: Although the patients with a rapid disease course could be differentiated at baseline in terms of PFT and CPI, the predictive accuracy of any single clinical variable as well as CPI and GAP remained low. GAP staging was unable to identify the majority of patients with a rapid disease progression. It is challenging to predict disease progression and mortality in IPF even with risk prediction models.

Overview

CoChat Summary

TL;DR

This retrospective cohort study of 132 patients with idiopathic pulmonary fibrosis (IPF) found that patients with rapid progression could be distinguished at baseline by pulmonary function and Composite Physiologic Index (CPI), but prediction of mortality remained poor overall. GAP staging was slightly better than CPI for 2-year mortality (0.67 vs 0.64), yet it still missed most rapid progressors.

Key findings

  • Among 132 included patients, disease course was rapid in 40 (30.3%), moderate in 37 (28.0%), and slow in 39 (29.5%); median survival was 42 months.
  • Baseline DLco % and CPI differed significantly between rapid progressors and the slower groups, but the predictive accuracy of investigated clinical variables was generally less than 0.80.
  • GAP staging identified all 12 patients in GAP stage III as rapid progressors, but 23 of 40 rapid progressors were in GAP stages I or II; 40% of rapid progressors were in GAP stage II and 25% in stage I.
  • For 2-year mortality, GAP had slightly better accuracy than CPI (0.67 vs 0.64); the best multivariable model included age, gender, and CPI.

Methods

  • Retrospective cohort study at Kuopio University Hospital using medical records from 2002–2012; patients were re-evaluated under 2011 international IPF diagnostic guidelines.
  • Initial evaluation included 223 patients with pulmonary fibrosis; 132 patients with IPF were included after excluding non-IPF diagnoses.
  • Patients were grouped by observed survival after diagnosis: rapid (<2 years), moderate (2–5 years), and slow (>5 years); analyses used group comparisons, Kaplan-Meier/log-rank survival analysis, ROC curve analysis, and Cox proportional hazards models.

Limitations

  • The paper states the study was relatively small and retrospectively collected.
  • It notes possible selection/coding issues: some IPF patients may have been missed due to hospital register coding, and some frail patients may never have received diagnostic procedures, so IPF may not have been established.
  • There was missing information, including spirometry results from 6 cases, preventing GAP stage calculation for those patients.
  • Evident from the text: the cohort spans 2002–2012, during which IPF diagnostic criteria changed, although the authors re-assessed cases using 2011 criteria.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12890-019-0996-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The most common comorbidities were cardiovascular diseases including coronary artery disease, hypertension and cerebral infarction. Patients with a rapid disease course (survival less than 2 years) had less lung cancer (0%) than patients with a moderate course of disease (survival 2–5 years) (14.3%, p = 0.026). Patients with a slow course of disease (survival more than 5 years) had more asthma (26.7%) than patients with shorter survival times (11.0%, p = 0.043). CVD, cardiovascular diseases; CAD; coronary artery disease; HT, hypertension; CI, cerebral infarction; DM, diabetes (types I and II); HF, heart failure for any reason; GER, gastroesophageal reflux; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea
Fig. 1 The most common comorbidities were cardiovascular diseases including coronary artery disease, hypertension and cerebral infarction. Patients with a rapid disease course (survival less than 2 years) had less lung cancer (0%) than patients with a moderate course of disease (survival 2–5 years) (14.3%, p = 0.026). Patients with a slow course of disease (survival more than 5 years) had more asthma (26.7%) than patients with shorter survival times (11.0%, p = 0.043). CVD, cardiovascular diseases; CAD; coronary artery disease; HT, hypertension; CI, cerebral infarction; DM, diabetes (types I and II); HF, heart failure for any reason; GER, gastroesophageal reflux; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apneaCC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations

34 more claims

Create a free account to see all 62 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 12
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 30 references

Cited by

See all 23

Metadata

Authors
Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R.
Affiliations
  • University of Eastern Finland (FI)
  • Kuopio University Hospital (FI)
  • Oulu University Hospital (FI)
Corresponding author
Kärkkäinen, Miia
Venue
BMC Pulmonary Medicine
Published
2019-11-29
Volume
19
Issue
1
Pages
228-228
ISSN
1471-2466 (ISSN-L)
OpenAlex
W2990821151
Cited by
23
References
30
Citations by year
2026: 1 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 3
FWCI
3.12
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Pulmonary Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö (None)
  • The Organization for Respiratory Health in Finland (None)
  • Väinö and Laina Kivi Foundation (None)
  • The Kuopio Region Respiratory Foundation (None)
  • Jalmari and Rauha Ahokas Foundation (None)
  • Center of Medicine and Clinical Research in Kuopio University Hospital (None)
  • the North Savo Regional Fund of the Finnish Cultural Foundation (None)
  • the state subsidy of the Kuopio University Hospital (None)
  • Research Director of Kuopio University Hospital (None)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
idiopathic pulmonary fibrosis, disease progression, mortality prediction, composite physiologic index, pulmonary function tests, risk stratification, heart failure, comorbidities, prognostic factors
MeSH terms
Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Disease Progression, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of disease progression subgroups in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12890-019-0996-2
The paper
Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R. (2019). Comparison of disease progression subgroups in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-019-0996-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.